Literature DB >> 11907645

Ribavirin's antiviral mechanism of action: lethal mutagenesis?

Shane Crotty1, Craig Cameron, Raul Andino.   

Abstract

Ribavirin, an antiviral drug discovered in 1972, is interesting and important for three reasons: (a) it exhibits antiviral activity against a broad range of RNA viruses; (b) it is currently used clinically to treat hepatitis C virus infections, respiratory syncytial virus infections, and Lassa fever virus infections; and (c) ribavirin's mechanism of action has remained unclear for many years. Here we recount the history of ribavirin and review recent reports regarding ribavirin's mechanism of action, including our studies demonstrating that ribavirin is an RNA virus mutagen and ribavirin's primary antiviral mechanism of action against a model RNA virus is via lethal mutagenesis of the RNA virus genomes. Implications for the development of improved versions of ribavirin and for the development of novel antiviral drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11907645     DOI: 10.1007/s00109-001-0308-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  79 in total

1.  Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1).

Authors:  Sotirios G Zarogiannis; James W Noah; Asta Jurkuvenaite; Chad Steele; Sadis Matalon; Diana L Noah
Journal:  Life Sci       Date:  2012-01-16       Impact factor: 5.037

Review 2.  Examining the theory of error catastrophe.

Authors:  Jesse Summers; Samuel Litwin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence.

Authors:  Ana Grande-Pérez; Gema Gómez-Mariano; Pedro R Lowenstein; Esteban Domingo
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.

Authors:  J Cao; X Sun; X Zhang; D Chen
Journal:  Clin Transl Oncol       Date:  2017-10-30       Impact factor: 3.405

5.  Lethal mutagenesis in viruses and bacteria.

Authors:  Peiqiu Chen; Eugene I Shakhnovich
Journal:  Genetics       Date:  2009-07-20       Impact factor: 4.562

Review 6.  Molecular targets for flavivirus drug discovery.

Authors:  Aruna Sampath; R Padmanabhan
Journal:  Antiviral Res       Date:  2008-09-15       Impact factor: 5.970

7.  Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence.

Authors:  Jianxiong Zeng; Haiwei Wang; Xiaochun Xie; Chen Li; Guohui Zhou; Decheng Yang; Li Yu
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

8.  Model systems for the study of human norovirus Biology.

Authors:  S Vashist; D Bailey; A Putics; I Goodfellow
Journal:  Future Virol       Date:  2009-07       Impact factor: 1.831

9.  Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.

Authors:  Julia Dietz; Sven-Eric Schelhorn; Daniel Fitting; Ulrike Mihm; Simone Susser; Martin-Walter Welker; Caterina Füller; Martin Däumer; Gerlinde Teuber; Heiner Wedemeyer; Thomas Berg; Thomas Lengauer; Stefan Zeuzem; Eva Herrmann; Christoph Sarrazin
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.

Authors:  Nirav R Shah; Amanda Sunderland; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.